Catalyst Wire Dossier Catalyst Wire Dossier

BIND-014

docetaxel nanoparticle · BIND Therapeutics
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for BIND-014, covering 2016-02-09 to 2016-04-18. Get the full timeline:

Most recent: Clinical Trial Update: A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer [Phase 2]

See pricing